Labreche D G, Kondos G T, Bartels D W, Bauman J L
College of Pharmacy, University of Connecticut, Farmington.
Ann Pharmacother. 1993 Sep;27(9):1048-52. doi: 10.1177/106002809302700906.
To examine the effects of diltiazem and propranolol on plasma lipoproteins in a double-blind, comparative trial.
Twenty-one mild-to-moderate hypertensive patients.
Following discontinuation of previous antihypertensive treatments, and a 4-week, single-blind, placebo run-in, subjects were randomized to receive sustained-release diltiazem or propranolol. Total cholesterol, high-density lipoproteins (HDL), low-density lipoproteins (LDL), and very-low-density lipoproteins (VLDL) were measured during placebo administration and after 12-16 weeks of treatment.
No significant changes in plasma lipoprotein concentrations were noted in either the diltiazem or propranolol group compared with baseline values or each other. Marked variation in HDL, LDL, and VLDL were noted following drug treatment and in eight subjects whose lipoprotein concentrations were remeasured prior to drug treatment during the placebo period. The alterations were bidirectional, and similar in magnitude to those found following drug treatment.
In many cases, changes in plasma lipoproteins reported to be a consequence of antihypertensive treatment may merely reflect normal intrapatient variability.
在一项双盲对照试验中研究地尔硫䓬和普萘洛尔对血浆脂蛋白的影响。
21例轻至中度高血压患者。
在停用先前的抗高血压治疗后，进行为期4周的单盲安慰剂导入期，然后将受试者随机分为接受缓释地尔硫䓬或普萘洛尔治疗。在给予安慰剂期间以及治疗12 - 16周后，测量总胆固醇、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）和极低密度脂蛋白（VLDL）。
与基线值相比，地尔硫䓬组或普萘洛尔组的血浆脂蛋白浓度均无显著变化，两组之间也无显著差异。在药物治疗后以及安慰剂期内8例在药物治疗前重新测量脂蛋白浓度的受试者中，观察到HDL、LDL和VLDL有明显变化。这些变化是双向的，且幅度与药物治疗后相似。
在许多情况下，据报道为抗高血压治疗结果的血浆脂蛋白变化可能仅仅反映了患者体内的正常变异性。
